Market News & Trends
SteadyMed Raises $30 Million
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
SteadyMed Raises $30 Million
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to…
Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to…
Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine, a drug currently being trialed by ImmunoGen, has the potential to solve a major unmet medical need for patients with platinum-resistant ovarian cancer,…
Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine, a drug currently being trialed by ImmunoGen, has the potential to solve a major unmet medical need for patients with platinum-resistant ovarian cancer,…
LDC & SOTIO Enter License & Collaboration Agreement
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI), and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive…
Key Milestone Reached in Catalyst’s Subcutaneous Factor IX Program
Catalyst Biosciences, Inc. recently announced it has achieved a key milestone under its collaboration with ISU Abxis to advance the Factor IX program toward its…
Intellia Therapeutics Granted CRISPR/Cas9 Genome Editing Technology Patent
Intellia Therapeutics recently announced that the European Patent Office (EPO) has decided to grant a patent broadly covering the CRISPR/Cas9 genome editing technology. The patent…
Idera Pharmaceuticals Advances Investigational Treatment
Idera Pharmaceuticals, Inc. recently announced successful completion of the Phase I portion of the ongoing Phase I/II clinical trial of intratumoral IMO-2125. Intratumoral IMO-2125 is…
Nabriva Therapeutics Announces Enrollment Completion for Phase 3 Clinical Trial
Nabriva Therapeutics AG recently announced it has completed enrollment in its first lefamulin evaluation against pneumonia (LEAP 1) Phase 3 clinical trial. LEAP 1, which…
Lhasa & Optibrium Enter Research & Product Development Collaboration
Optibrium and Lhasa Limited recently announced they have formed a collaborative partnership to research next-generation drug metabolism modelling. Results from the work will be used…
Aptar Pharma Unveils its eDose Counter for MDIs at RDD Europe 2017
Aptar Pharma recently announced it will present its patented eDose Counter for Metered Dose Inhalers (MDIs), designed to be easy-to-use and reliable, and contributes to…
Aptar Pharma Unveils its eDose Counter for MDIs at RDD Europe 2017
Aptar Pharma recently announced it will present its patented eDose Counter for Metered Dose Inhalers (MDIs), designed to be easy-to-use and reliable, and contributes to…
Vectura Group Launches Utibron Neohaler in the US
Vectura Group plc recently announced that Sunovion Pharmaceuticals Inc. has launched Utibron Neohaler (indacaterol/glycopyrrolate) in the US. Sunovion entered into an exclusive license agreement with…
UroGen Pharma Announces Enrollment of First Patient in Phase III Clinical Trial
UroGen Pharma Ltd. recently announced the first patient has been enrolled in the OLYMPUS trial, an open-label, single-arm pivotal Phase III clinical trial of MitoGel,…
Tetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase III Clinical Trial
Tetraphase Pharmaceuticals, Inc. recently announced completion of enrollment in IGNITE4, its ongoing Phase III clinical trial evaluating the efficacy and safety of intravenous (IV) eravacycline…
SteadyMed Completes Clinical Validation Study of Trevyent Study; Confirms Performance of PatchPump Technology
SteadyMed Ltd. recently announced the successful completion of a clinical study for its lead drug product candidate, Trevyent. Trevyent is a combination of the company’s…
Caris Life Sciences Announces Study Results for ADAPT Biotargeting System
Caris Life Sciences recently announced results of a study that demonstrate the ability of the company's ADAPT Biotargeting System to identify the molecular target, a…
Bio-Path Holdings Presents Study Results Showing Potential of BP1002
Bio-Path Holdings, Inc. recently announced results of preclinical in vitro and in vivo studies supporting the potential of BP1002 in the treatment of aggressive non-Hodgkin’s…
